Wednesday, June 23, 2021 12:22:25 PM
Analysts gave the Adaptimmune Therapeutics plc (ADAP) stock a consensus recommendation rating of a Hold, calculated at a mean rating of 2.60. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended ADAP as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Adaptimmune Therapeutics plc’s EPS for the current quarter is expected to be -$0.24.
Instantly ADAP was in red as seen at the end of in last trading. With action -6.76%, the performance over the past five days has been red. The drop to weekly highs of 4.22 on Tuesday, 06/22/21 subtracted -1.03% to the stock’s daily price. The company’s shares are showing year-to-date downside of -28.39%, with the 5-day performance at -6.76% in the red. However, in the 30-day time frame, Adaptimmune Therapeutics plc (NASDAQ:ADAP) is -24.17% down. Looking at the short shares, we see there were 3.84 million shares sold at short interest cover period of 5.03 days.
The consensus price target for the stock as assigned by Wall Street analysts is $10.29, meaning bulls need an upside of 62.49% from its current market value. According to analyst projections, ADAP’s forecast low is $4.00 with $17.00 as the target high. To hit the forecast high, the stock’s price needs a -340.41% plunge from its current level, while the stock would need to soar -3.63% for it to hit the projected low.
Adaptimmune Therapeutics plc (ADAP) estimates and forecasts
Data shows that the Adaptimmune Therapeutics plc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -21.38% over the past 6 months, a -11.11% in annual growth rate that is considerably lower than the industry average of 9.00%. Year-over-year growth is forecast to reach -32.30% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of $1.36 million. 7 analysts are of the opinion that Adaptimmune Therapeutics plc’s revenue for the quarter ending Sep 2021 will be $460k. The company’s revenue for the corresponding quarters a year ago was $930k and $1.19 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 46.20%. The estimates for the next quarter sales put growth at -61.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -24.90%. The 2021 estimates are for Adaptimmune Therapeutics plc earnings to increase by 30.10%, but the outlook for the next 5-year period is at 1.00% per year.
SOURCE: https://marketingsentinel.com/2021/06/23/adaptimmune-therapeutics-plc-nasdaq-adap-the-most-interesting-shares-today/
And the stunning truth of the matter is that this generation, save the military, doesn’t value freedom. Instead, it values comfort. It values convenience and coddling, and conformity.
Recent ADAP News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 11:23:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:05:55 AM
- U.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices Climb • IH Market News • 08/12/2024 09:47:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 11:00:19 AM
- Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor • Business Wire • 08/02/2024 12:20:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:15:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:39:58 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:14:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:34:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:13:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:07:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:31:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:02:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:00:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:46:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 12:13:01 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM